Abbott Laboratories (ABT) reports steady earnings with robust growth in medical devices, while navigating challenges in diagnostics and nutrition segments.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories (NYSE:ABT) reported first-quarter 2026 results that management said were “aligned with our expectations ...

Shares of Abbott Laboratories (ABT) have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences Corporation (EXAS), taking place at a revenue ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results. The 15-minute test from Abbott Laboratories ...

Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said its nutrition unit continued to notch soft sales during the first quarter. The company, which sells ...

Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories that President Donald Trump has repeatedly lauded ― particularly, the risk of infection to ...

Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected ...

Robert Ford (Chairman, President & CEO) said Q1 results were “aligned with our expectations for the start of the year,” citing “adjusted earnings per share of $1.15, consistent with our guidance ...

Abbott Diabetes Care said it had received reports of more than 700 injuries that may be associated with malfunctioning sensors. By Amanda Holpuch ByHeart, the maker of the product, has been linked to ...